Medpace Holdings Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while State Street Technology Select Sector SPDR ETF trades at $178.9. Which is the better fit depends on your goals.
| MEDP | XLK | |
|---|---|---|
Market Cap | $15.08B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $620.59 | $198.21 |
52-Week Low | $308.88 | $127.49 |
Enterprise Value | $14.55B | — |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
XLK trades at $175.71 with minimal daily movement (+0.07%), showing technical bearish signals while maintaining strong year-to-date performance of 33%. The ETF's technical indicators show selling pressure with bearish moving averages, though oscillators remain neutral. Recent news highlights XLK as the top-performing sector SPDR in 2026, driven by technology sector strength and institutional inflows.
Outlook remains positive given technology sector momentum and strong earnings expectations, though concentration risk and technical weakness warrant monitoring. The ETF benefits from sector leadership but faces headwinds from potential Fed policy shifts and market volatility. Current levels near pivot point resistance at $176 suggest near-term consolidation.
Trailing returns across standard periods
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →